Expression of bone-regulating factors osteoprotegerin (OPG) and receptor activator of NF-κB ligand (RANKL) in heterotopic vascular ossification

被引：7

作者：

Al-Fakhri, N

Hofbauer, LC

Preissner, KT

Franke, FE

Schoppet, M

机构：

[1] Univ Marburg, Dept Clin Chem, D-35033 Marburg, Germany

[2] Univ Marburg, Dept Internal Med, D-35033 Marburg, Germany

[3] Univ Marburg, Dept Gastroenterol & Endocrinol, D-35033 Marburg, Germany

[4] Univ Marburg, Dept Cardiol, D-35033 Marburg, Germany

[5] Univ Giessen, Dept Biochem, Giessen, Germany

[6] Univ Giessen, Dept Pathol, Giessen, Germany

来源：

THROMBOSIS AND HAEMOSTASIS | 2005年 / 94卷 / 06期

关键词：

D O I：

10.1160/TH05-06-1335

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

[No abstract available]

引用

页码：1335 / 1337

页数：3

共 14 条

[1]

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].

Bucay, N ;

Sarosi, I ;

Dunstan, CR ;

Morony, S ;

Tarpley, J ;

Capparelli, C ;

Scully, S ;

Tan, HL ;

Xu, WL ;

Lacey, DL ;

Boyle, WJ ;

Simonet, WS .

GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268

[2]

Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin [J].

Collin-Osdoby, P .

CIRCULATION RESEARCH, 2004, 95 (11) :1046-1057

[3]

T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction [J].

Colucci, S ;

Brunetti, G ;

Rizzi, R ;

Zonno, A ;

Mori, G ;

Colaianni, G ;

Del Prete, D ;

Faccio, R ;

Liso, A ;

Capalbo, S ;

Liso, V ;

Zallone, A ;

Grano, M .

BLOOD, 2004, 104 (12) :3722-3730

[4]

Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads [J].

Doherty, TM ;

Asotra, K ;

Fitzpatrick, LA ;

Qiao, JH ;

Wilkin, DJ ;

Detrano, RC ;

Dunstan, CR ;

Shah, PK ;

Rajavashisth, TB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (20) :11201-11206

[5]

Rationale for the role of osteoclast-like cells in arterial calcification [J].

Doherty, TM ;

Uzui, H ;

Fitzpatrick, LA ;

Tripathi, PV ;

Dunstan, CR ;

Asotra, K ;

Rajavashisth, TB .

FASEB JOURNAL, 2002, 16 (06) :577-582

[6]

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL [J].

Emery, JG ;

McDonnell, P ;

Burke, MB ;

Deen, KC ;

Lyn, S ;

Silverman, C ;

Dul, E ;

Appelbaum, ER ;

Eichman, C ;

DiPrinzio, R ;

Dodds, RA ;

James, IE ;

Rosenberg, M ;

Lee, JC ;

Young, PR .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) :14363-14367

[7]

TRAIL expression in vascular smooth muscle [J].

Gochuico, BR ;

Zhang, J ;

Ma, BY ;

Marshak-Rothstein, A ;

Fine, A .

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2000, 278 (05) :L1045-L1050

[8]

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases [J].

Hofbauer, LC ;

Schoppet, M .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (04) :490-495

[9]

Calcification of the aortic arch - Risk factors and association with coronary heart disease, stroke, and peripheral vascular disease [J].

Iribarren, C ;

Sidney, S ;

Sternfeld, B ;

Browner, WS .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (21) :2810-2815

[10]

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis [J].

Min, H ;

Morony, S ;

Sarosi, I ;

Dunstan, CR ;

Capparelli, C ;

Scully, S ;

Van, G ;

Kaufman, S ;

Kostenuik, PJ ;

Lacey, DL ;

Boyle, TJ ;

Simonet, WS .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (04) :463-474

← 1 2 →